1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Sofinnova Ventures Inc Buys Novo Nordisk A/S, Allergan PLC, Alnylam Pharmaceuticals Inc, Sells Ascendis Pharma A/S, Sanofi SA, Gilead Sciences Inc

Investment company Sofinnova Ventures Inc buys Novo Nordisk A/S, Allergan PLC, Alnylam Pharmaceuticals Inc, Halozyme Therapeutics Inc, Blueprint Medicines Corp, AnaptysBio Inc, Neurocrine Biosciences Inc, Akebia Therapeutics Inc, Insmed Inc, Macrogenics Inc, TG Therapeutics Inc, XBiotech Inc, Arqule Inc, Biohaven Pharmaceutical Holding Co, Portola Pharmaceuticals Inc, Adverum Biotechnologies Inc, sells Ascendis Pharma A/S, Sanofi SA, Gilead Sciences Inc, Biomarin Pharmaceutical Inc, Tesaro Inc, Incyte Corp, Rigel Pharmaceuticals Inc, Sarepta Therapeutics Inc, Reata Pharmaceuticals Inc, Aimmune Therapeutics Inc, Clovis Oncology Inc, Puma Biotechnology Inc, Epizyme Inc, Heron Therapeutics Inc, Five Prime Therapeutics Inc, Immunogen Inc, Conatus Pharmaceuticals Inc, GW Pharmaceuticals PLC, FibroGen Inc, PDS Biotechnology Corp, Pacira BioSciences Inc, Syndax Pharmaceuticals Inc, Kala Pharmaceuticals Inc during the 3-months ended 2019Q1, according to the most recent filings of the investment company, Sofinnova Ventures Inc. As of 2019Q1, Sofinnova Ventures Inc owns 62 stocks with a total value of $954 million. These are the details of the buys and sells.

For the details of Sofinnova Ventures Inc's stock buys and sells, go to https://www.gurufocus.com/guru/sofinnova+ventures+inc/current-portfolio/portfolio

These are the top 5 holdings of Sofinnova Ventures Inc
  1. Ascendis Pharma A/S (ASND) - 998,538 shares, 12.32% of the total portfolio. Shares reduced by 33.37%
  2. Amarin Corp PLC (AMRN) - 5,208,305 shares, 11.33% of the total portfolio.
  3. Principia Biopharma Inc (PRNB) - 2,038,208 shares, 7.26% of the total portfolio.
  4. Natera Inc (NTRA) - 3,100,560 shares, 6.70% of the total portfolio.
  5. ObsEva SA (OBSV) - 4,749,623 shares, 6.37% of the total portfolio.
New Purchase: Allergan PLC (AGN)

Sofinnova Ventures Inc initiated holding in Allergan PLC. The purchase prices were between $132.09 and $160.79, with an estimated average price of $144.95. The stock is now traded at around $136.71. The impact to a portfolio due to this purchase was 1.36%. The holding were 88,665 shares as of .

New Purchase: Novo Nordisk A/S (NVO)

Sofinnova Ventures Inc initiated holding in Novo Nordisk A/S. The purchase prices were between $46.07 and $52.63, with an estimated average price of $49.1. The stock is now traded at around $46.94. The impact to a portfolio due to this purchase was 1.36%. The holding were 247,734 shares as of .

New Purchase: Alnylam Pharmaceuticals Inc (ALNY)

Sofinnova Ventures Inc initiated holding in Alnylam Pharmaceuticals Inc. The purchase prices were between $72.76 and $93.45, with an estimated average price of $83.46. The stock is now traded at around $68.07. The impact to a portfolio due to this purchase was 1.04%. The holding were 106,616 shares as of .

New Purchase: Halozyme Therapeutics Inc (HALO)

Sofinnova Ventures Inc initiated holding in Halozyme Therapeutics Inc. The purchase prices were between $13.94 and $17.58, with an estimated average price of $16.2. The stock is now traded at around $15.79. The impact to a portfolio due to this purchase was 0.68%. The holding were 401,329 shares as of .

New Purchase: Blueprint Medicines Corp (BPMC)

Sofinnova Ventures Inc initiated holding in Blueprint Medicines Corp. The purchase prices were between $48.7 and $86.6, with an estimated average price of $73.56. The stock is now traded at around $77.20. The impact to a portfolio due to this purchase was 0.6%. The holding were 71,866 shares as of .

New Purchase: Akebia Therapeutics Inc (AKBA)

Sofinnova Ventures Inc initiated holding in Akebia Therapeutics Inc. The purchase prices were between $5.41 and $8.73, with an estimated average price of $6.83. The stock is now traded at around $5.79. The impact to a portfolio due to this purchase was 0.44%. The holding were 516,761 shares as of .

Added: AnaptysBio Inc (ANAB)

Sofinnova Ventures Inc added to a holding in AnaptysBio Inc by 291.48%. The purchase prices were between $61.38 and $75.39, with an estimated average price of $69.01. The stock is now traded at around $72.52. The impact to a portfolio due to this purchase was 0.56%. The holding were 97,948 shares as of .

Added: Neurocrine Biosciences Inc (NBIX)

Sofinnova Ventures Inc added to a holding in Neurocrine Biosciences Inc by 82.77%. The purchase prices were between $69.31 and $91.53, with an estimated average price of $83.53. The stock is now traded at around $78.89. The impact to a portfolio due to this purchase was 0.47%. The holding were 112,406 shares as of .

Added: Macrogenics Inc (MGNX)

Sofinnova Ventures Inc added to a holding in Macrogenics Inc by 57.32%. The purchase prices were between $11.11 and $25.6, with an estimated average price of $17.21. The stock is now traded at around $16.27. The impact to a portfolio due to this purchase was 0.36%. The holding were 523,756 shares as of .

Added: Biohaven Pharmaceutical Holding Co Ltd (BHVN)

Sofinnova Ventures Inc added to a holding in Biohaven Pharmaceutical Holding Co Ltd by 28.23%. The purchase prices were between $34.52 and $53.29, with an estimated average price of $43.04. The stock is now traded at around $61.72. The impact to a portfolio due to this purchase was 0.15%. The holding were 124,952 shares as of .

Sold Out: Sanofi SA (SNY)

Sofinnova Ventures Inc sold out a holding in Sanofi SA. The sale prices were between $40.83 and $45.43, with an estimated average price of $42.82.

Sold Out: Gilead Sciences Inc (GILD)

Sofinnova Ventures Inc sold out a holding in Gilead Sciences Inc. The sale prices were between $62.53 and $70.05, with an estimated average price of $66.46.

Sold Out: Tesaro Inc (TSRO)

Sofinnova Ventures Inc sold out a holding in Tesaro Inc. The sale prices were between $74.02 and $74.96, with an estimated average price of $74.7.

Sold Out: Rigel Pharmaceuticals Inc (RIGL)

Sofinnova Ventures Inc sold out a holding in Rigel Pharmaceuticals Inc. The sale prices were between $2 and $2.65, with an estimated average price of $2.29.

Sold Out: Sarepta Therapeutics Inc (SRPT)

Sofinnova Ventures Inc sold out a holding in Sarepta Therapeutics Inc. The sale prices were between $106.67 and $151.68, with an estimated average price of $128.32.

Sold Out: Aimmune Therapeutics Inc (AIMT)

Sofinnova Ventures Inc sold out a holding in Aimmune Therapeutics Inc. The sale prices were between $21.15 and $26.37, with an estimated average price of $23.55.



Here is the complete portfolio of Sofinnova Ventures Inc. Also check out:

1. Sofinnova Ventures Inc's Undervalued Stocks
2. Sofinnova Ventures Inc's Top Growth Companies, and
3. Sofinnova Ventures Inc's High Yield stocks
4. Stocks that Sofinnova Ventures Inc keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK